Erratum

The abstract to Frantz, RP: Positioning newer agents: Riociguat, selexipag, and oral treprostinil in the current landscape on page 193 of Advances in Pulmonary Hypertension, Volume 15, number 4 contained an error. The sentence beginning in line 10 should read: “Riociguat is a soluble guanylate cyclase stimulator that has been shown to be beneficial, including in combination with an endothelin receptor antagonist, and may be a useful alternative to a PDE5 inhibitor in properly selected patients.